Earnings summaries and quarterly performance for Contineum Therapeutics.
Executive leadership at Contineum Therapeutics.
Board of directors at Contineum Therapeutics.
Research analysts covering Contineum Therapeutics.
Recent press releases and 8-K filings for CTNM.
Contineum Therapeutics Reviews 2025 Accomplishments and Outlines 2026 Catalysts
CTNM
New Projects/Investments
Guidance Update
- Contineum Therapeutics (CTNM) executed four clinical studies in 2025, its first full year as a public company, including completing a Phase 1b PET receptor occupancy study for PIPE-791 and fully enrolling a Phase 1b exploratory study for chronic pain.
- The company is initiating a Phase 2 clinical proof of concept study for PIPE-791 in idiopathic pulmonary fibrosis (IPF) before the end of December 2025, aiming for a best-in-class approach with QD dosing, over 90% receptor occupancy, and no hypotension signal, differentiating it from Bristol-Myers Squibb's LPA1 antagonist.
- Contineum reported VISTA data for PIPE-307 in relapsing remitting MS earlier in December 2025, which missed its primary endpoint.
- Key catalysts for 2026 include top-line data from the PIPE-791 chronic pain study in the first half of 2026 and the expected Q4 2026 readout of Bristol-Myers Squibb's Phase 3 data for their LPA1 antagonist.
Dec 3, 2025, 6:20 PM
Contineum Highlights 2025 Clinical Progress and 2026 Catalysts
CTNM
New Projects/Investments
Guidance Update
- Contineum (CTNM) completed its first full year as a public company in 2025, executing on four clinical studies.
- The company is initiating a Phase 2 clinical proof of concept study for PIPE-791 in idiopathic pulmonary fibrosis (IPF) before the end of December, following a successful Phase 1b PET receptor occupancy study that validated dose selections.
- Top-line data from an exploratory Phase 1b study of PIPE-791 in chronic pain is anticipated in the first half of 2026.
- Contineum reported that its PIPE-307 VISTA study missed its primary endpoint.
- A key catalyst for Contineum in 2026 is the expected Q4 2026 readout of Bristol Myers Squibb's (BMS) Phase 3 data for their LPA1 antagonist, which could validate the LPA1 mechanism in IPF.
Dec 3, 2025, 6:20 PM
Contineum Therapeutics Reports Negative Topline Phase 2 Trial Results for PIPE-307 in RRMS
CTNM
New Projects/Investments
- Contineum Therapeutics, Inc. (CTNM) announced on November 20, 2025, topline data from its Phase 2 PIPE-307 VISTA trial for the treatment of relapsing-remitting multiple sclerosis (RRMS).
- The trial demonstrated acceptable safety and tolerability for PIPE-307 at both doses.
- However, the trial did not meet its prespecified primary or secondary efficacy endpoints, showing no significant change in binocular 2.5% low contrast letter acuity across treatment arms.
- The company expressed disappointment with these results.
Nov 20, 2025, 9:07 PM
Contineum Therapeutics Reports Q3 2025 Financial Results and Clinical Milestones
CTNM
Earnings
Guidance Update
New Projects/Investments
- Contineum Therapeutics reported a net loss of $12.8 million for the third quarter ended September 30, 2025, compared to $10.3 million for the prior-year quarter.
- As of September 30, 2025, the company held $182.4 million in cash, cash equivalents, and marketable securities, and has extended its projected cash runway to fund planned operations through 2028.
- Key clinical development milestones include the anticipated reporting of topline data from the PIPE-307 Phase 2 VISTA trial in Q4 2025 and the initiation of a global PIPE-791 Phase 2 clinical trial in idiopathic pulmonary fibrosis (IPF) in Q4 2025.
- The company has made a strategic decision to defer the initiation of its PIPE-791 PrMS and CTX-343 clinical development efforts.
Oct 30, 2025, 8:09 PM
Contineum Therapeutics Reports Positive Topline Data for PIPE-791 Phase 1b PET Trial
CTNM
New Projects/Investments
- Contineum Therapeutics, Inc. announced positive topline data from its Phase 1b Positron Emission Tomography (PET) trial of PIPE-791 on September 18, 2025.
- The trial confirmed that PIPE-791 achieved high LPA1 brain receptor occupancy (RO) in both healthy volunteers and progressive multiple sclerosis (PrMS) patients, demonstrating a clear pharmacokinetic correlation between drug exposure and receptor engagement.
- PIPE-791 showed a safety and tolerability profile consistent with previous clinical studies, and the company anticipates its planned doses for future Phase 2 trials in idiopathic pulmonary fibrosis (IPF) and PrMS will exceed 90% target coverage at trough with once daily dosing.
Sep 18, 2025, 12:16 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more